Evolus, Inc. (EOLS), a performance beauty company, Monday announced positive topline results from a U.S. pivotal study of Evolysse Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.
The study met its primary goal of non-inferiority compared to Galderma's Restylane. The study also showed statistical superiority versus Restylane with a mean mid-face volume deficit severity score difference of -0.26.
Evolus has already submitted a PMA application for Evolysse Sculpt with approval expected in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.